gemcitabine + fluorouracil + leucovorin + irinotecan + oxaliplatin + dexamethasone

**Gemcitabine + fluorouracil + leucovorin + irinotecan + oxaliplatin + dexamethasone** is a six-drug chemotherapy combination primarily investigated for advanced pancreatic cancer. It merges gemcitabine (a nucleoside metabolic inhibitor that incorporates into DNA to halt replication), fluorouracil (a pyrimidine analog inhibiting thymidylate synthase and incorporating into RNA/DNA), leucovorin (folinic acid to potentiate fluorouracil), irinotecan (a topoisomerase I inhibitor causing DNA damage), oxaliplatin (a platinum compound forming DNA crosslinks), and dexamethasone (a corticosteroid mitigating inflammation and chemotherapy-induced nausea). This polychemotherapy aims to synergistically target multiple cancer cell pathways but is experimental, with feasibility shown only in phase I settings using attenuated doses due to overlapping toxicities like myelosuppression, diarrhea, and neuropathy. No standard regimen or approval exists; related five-drug subsets (e.g., oxaliplatin + irinotecan + fluorouracil + leucovorin ± gemcitabine) have been tested in pancreatic cancer trials.[3][1]